| 001 | 179660 | ||
| 005 | 20240229145550.0 | ||
| 024 | 7 | _ | |a 10.1021/acs.molpharmaceut.2c00070 |2 doi |
| 024 | 7 | _ | |a pmid:35467350 |2 pmid |
| 024 | 7 | _ | |a 1543-8384 |2 ISSN |
| 024 | 7 | _ | |a 1543-8392 |2 ISSN |
| 024 | 7 | _ | |a altmetric:127283551 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-00832 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Liolios, Christos |0 P:(DE-He78)c8c77862236d6e9b311705b9ecdf0413 |b 0 |e First author |
| 245 | _ | _ | |a Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors. |
| 260 | _ | _ | |a Washington, DC |c 2022 |b American Chemical Society |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1707313297_6047 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:E030# / 2022 Jul 4;19(7):2231-2247 / German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. |
| 520 | _ | _ | |a Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) have both been used in nuclear medicine as targets for molecular imaging and therapy of prostate (PCa) and breast cancer (BCa). Three bioconjugate probes, the PSMA specific: [68Ga]Ga-1, ((HBED-CC)-Ahx-Lys-NH-CO-NH Glu or PSMA-11), the GRPR specific: [68Ga]Ga-2, ((HBED-CC)-4-amino-1-carboxymethyl piperidine-[D-Phe6, Sta13]BN(6-14), a bombesin (BN) analogue), and 3 (the BN analogue: 4-amino-1-carboxymethyl piperidine-[(R)-Phe6, Sta13]BN(6-14) connected with the fluorescent dye, BDP-FL), were synthesized and tested in vitro with PCa and BCa cell lines, more specifically, with PCa cells, PC-3 and LNCaP, with BCa cells, T47D, MDA-MB-231, and with the in-house created PSMA-overexpressing PC-3(PSMA), T47D(PSMA), and MDA-MB-231(PSMA). In addition, biomolecular simulations were conducted on the association of 1 and 2 with PSMA and GRPR. The PSMA overexpression resulted in an increase of cell-bound radioligand [68Ga]Ga-1 (PSMA) for PCa and BCa cells and also of [68Ga]Ga-2 (GRPR), especially in those cell lines already expressing GRPR. The results were confirmed by fluorescence-activated cell sorting with a PE-labeled PSMA-specific antibody and the fluorescence tracer 3. The docking calculations and molecular dynamics simulations showed how 1 enters the PSMA funnel region and how pharmacophore Glu-urea-Lys interacts with the arginine patch, the S1', and S1 subpockets by forming hydrogen and van der Waals bonds. The chelating moiety of 1, that is, HBED-CC, forms additional stabilizing hydrogen bonding and van der Waals interactions in the arene-binding site. Ligand 2 is diving into the GRPR transmembrane (TM) helical cavity, thereby forming hydrogen bonds through its amidated end, water-mediated hydrogen bonds, and π-π interactions. Our results provide valuable information regarding the molecular mechanisms involved in the interactions of 1 and 2 with PSMA and GRPR, which might be useful for the diagnostic imaging and therapy of PCa and BCa. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a GRPR |2 Other |
| 650 | _ | 7 | |a LNCaP |2 Other |
| 650 | _ | 7 | |a MD simulations |2 Other |
| 650 | _ | 7 | |a MD-MB231 |2 Other |
| 650 | _ | 7 | |a PC-3 |2 Other |
| 650 | _ | 7 | |a PET imaging |2 Other |
| 650 | _ | 7 | |a PSMA |2 Other |
| 650 | _ | 7 | |a T47D |2 Other |
| 650 | _ | 7 | |a breast cancer |2 Other |
| 650 | _ | 7 | |a prostate cancer |2 Other |
| 700 | 1 | _ | |a Patsis, Christos |0 P:(DE-He78)e41ce75a370dda1c81800f1e53d2d12a |b 1 |
| 700 | 1 | _ | |a Lambrinidis, George |0 0000-0002-2820-9338 |b 2 |
| 700 | 1 | _ | |a Tzortzini, Efpraxia |b 3 |
| 700 | 1 | _ | |a Roscher, Mareike |0 P:(DE-He78)1a25bc9516a97a13551ebd083356d24f |b 4 |
| 700 | 1 | _ | |a Bauder-Wüst, Ulrike |0 P:(DE-He78)033d979f00729281e709b85fe6cae972 |b 5 |
| 700 | 1 | _ | |a Kolocouris, Antonios |0 0000-0001-6110-1903 |b 6 |
| 700 | 1 | _ | |a Kopka, Klaus |0 P:(DE-He78)9793347ba83f527b81a22ab75af9378a |b 7 |
| 773 | _ | _ | |a 10.1021/acs.molpharmaceut.2c00070 |g p. acs.molpharmaceut.2c00070 |0 PERI:(DE-600)2132489-X |n 7 |p 2231-2247 |t Molecular pharmaceutics |v 19 |y 2022 |x 1543-8384 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:179660 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)c8c77862236d6e9b311705b9ecdf0413 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)e41ce75a370dda1c81800f1e53d2d12a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)1a25bc9516a97a13551ebd083356d24f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)033d979f00729281e709b85fe6cae972 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 7 |6 P:(DE-He78)9793347ba83f527b81a22ab75af9378a |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-29 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-12 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOL PHARMACEUT : 2021 |d 2022-11-12 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b MOL PHARMACEUT : 2021 |d 2022-11-12 |
| 920 | 1 | _ | |0 I:(DE-He78)E030-20160331 |k E030 |l Radiopharmazeutische Chemie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)F190-20160331 |k F190 |l NWG Cell Plasticity and Epigenetic Remodeling |x 1 |
| 920 | 0 | _ | |0 I:(DE-He78)E030-20160331 |k E030 |l Radiopharmazeutische Chemie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E030-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F190-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::